GETINGE, Sweden--(BUSINESS WIRE)-- Regulatory News:
Getinge Group has appointed Harald F. Stock as new President and Chief Executive Officer of ArjoHuntleigh, and Executive Vice President Extended Care Business Area. Harald will be a member of the Getinge Group Executive Management Team and will succeed Alex Myers, who will pursue a new role outside of the group.
Harald Stock has almost twenty years of experience and a successful track record in the healthcare industry. He most recently served as the chief executive officer of the Grünenthal Group, a globally operating, family-owned, research-oriented pharmaceutical company. Previously, he held executive positions with the Roche Group and at DePuy, the Orthopaedics Division of Johnson & Johnson. Harald holds a PhD. in inorganic chemistry from University of Heidelberg, Germany.
“I am very pleased to welcome Harald to the Group. Harald has vast experience in the industry and a very strong commercial background. He has a great track record of successfully improving business performance and will be an asset to the team,” says Johan Malmquist, CEO Getinge Group. “I would also like to express my gratitude to Alex Myers for his professional and dedicated work during his five years with ArjoHuntleigh and the Getinge Group’s Extended Care business area. Alex has developed the business and established a competitive structure following the merger of Arjo and Huntleigh. I wish him all the best and good luck with his new challenges as President & CEO of the global bed manufacturer, Hilding Anders Group.”
Harald will assume his new position as of 1 January 2014 and will report to Johan Malmquist, CEO Getinge Group.
GETINGE GROUP is a leading global provider of products and systems that contribute to quality enhancement and cost efficiency within healthcare and life sciences. We operate under the three brands of ArjoHuntleigh, GETINGE and MAQUET. ArjoHuntleigh focuses on patient mobility and wound management solutions. GETINGE provides solutions for infection control within healthcare and contamination prevention within life sciences. MAQUET specializes in solutions, therapies and products for surgical interventions, interventional cardiology and intensive care.
The information is such that Getinge AB must disclose in accordance with the Swedish Securities Market Act and/or the Financial Instruments Trading Act.
This information was brought to you by Cision http://news.cision.com
CEO, Getinge Group
Tel: +46 10 335 00 00
Source: Getinge Group